Excerpts

Our results demonstrated significant improvements in PFS and ORR with combination therapy and suggest a favorable trend in OS in HBV-related HCC.

Here, only log 2 (wb TMV) showed a borderline significant association with prognosis ( Table 5 ). 3.3.3.

consultant) and institutional surgical volume (≥150 RARPs per year) reached near significance in predicting proficiency in identifying lymph node metastases.

No significant predictors of proficiency emerged in the multivariable analysis, although hierarchy and surgical volume approached significance for nodal metastasis detection.

Pre-Treatment CFH Independently Predicts PFS in adv-cSCC Although baseline CFH levels were not statistically different between adv-cSCC patients with progression compared to those without progression, they showed a clear trend toward higher values in patients with disease progression.

As a sensitivity analysis, excluding participants with loss of MMR protein who did not undergo genetic testing, age, sex, and stage of CRC at diagnosis were significantly associated with MPC, while MMR protein expression was found to be marginally significant ( Supplementary Table S1 ).

As shown in Table 2 , the multivariate analysis revealed that only the CD3 + TIL density and the CD24 expression status significantly correlated with DFS and OS, although the correlation of the CD3 + TIL density with OS was borderline significant.

It decreased from 1256.8 in 2014 to 661.5 in 2017; then it showed an increasing trend, except for a mild decrease in 2021, and finally reached 1743.7 in 2023.

Parameter SumVarnc ( p = 0.044) showed a statistical trend towards differentiation as the HPV-positive group had higher values. 4.

These showed a similar relationship of these parameters to outcome, albeit less marked, with the mean R2* on air being significant (and O 2 approaching significance). 3.2.3.

While the lack of QoL data in a negative clinical trial can be considered almost insignificant, a positive trial represents the first step for a drug to obtain regulatory approval and be included in clinical guidelines and routine clinical practice.

[ 46 ] noted that higher BMI, particularly in obese patients (BMI ≥ 25 kg/m 2 ), was associated with a 25% lower risk of disease progression (HR = 0.75; 95% CI: 0.62–0.92), with a significant trend of decreasing progression risk with increasing BMI.

We found that mFOLFIRINOX was associated with significantly improved disease-free survival and a favorable trend toward better overall survival, independent of histological subtype.

Following initiation of therapy, both patient-reported and parent-reported outcomes showed a trend towards improvement and subsequently remained stable throughout the duration of treatment. 4.

In one study, a DNA microanalysis of samples from adult AML patients showed a trend for high levels of PRAME mRNA to correlate with improved overall survival (OS) [ 8 ].

As a result, only genes with highly significant and large differential changes in expression among all datasets were retained in the analysis.

Importantly, the association between ICI treatment duration and OS and PFS only showed marginal significance in the univariate analysis.

We further stratified patients who received LRT and found that the survival advantage associated with grade 2 irLI was present in patients with and without LRT ( Supplementary Figure S5A,C ), and the difference was statistically significant in PFS for those with LRT ( Supplementary Figure S5B ) and marginally significant for those without LRT ( Supplementary Figure S5D ).

In this dataset, the association between MTOR and CDK12 ( n = 2/13; p = 0.027) showed statistically significant co-occurrence, while the association between TP53 and CDK12 ( n = 1/10; p = 0.162) was close to significance.

While the overall analysis showed stability in functional outcomes post-surgery across the different metastasis groups, the nearly significant p -values for changes in KPS in patients with oligometastatic and multiple metastases suggest a trend toward functional decline.

As reported in the updated MACH-NC meta-analysis, age and Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) appeared as the only significant factors influencing CRT efficacy; in fact elderly patients showed a significant shorter Overall Survival (OS) ( p = 0.03) and a negative trend, although non-significant, in Event-Free Survival (EFS) ( p = 0.06) [ 14 ] if compared with younger patients (<65 years old).

No significant benefit in survival was found between smokers and non-smokers ( p = 0.916) ( Figure 2 A), although with a positive trend in non-smokers with a delta of 6 months.

However, only a subset of ADC features in our study showed a trend toward intergroup difference, none of which reached statistical significance.

60.7%, p = 0.049), while BRCA mutations showed a favorable trend.

These findings suggest that supportive care needs are similar across dosing strategies, with a possible trend toward more treatment interruptions in the fixed-dose group.